A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment
Status:
Completed
Trial end date:
2014-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this open-label, randomized, phase II study is to compare the safety and
efficacy of dovitinib versus sorafenib as first-line treatment in adult patients with
advanced Hepatocellular Carcinoma (HCC). This trial will be opened in countries of the
Asia-Pacific region.